<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03759262</url>
  </required_header>
  <id_info>
    <org_study_id>CHLA-18-00362</org_study_id>
    <nct_id>NCT03759262</nct_id>
  </id_info>
  <brief_title>Ultra-high Dose Vitamin D for HSCT</brief_title>
  <official_title>Pilot Study of Transplant-related Events in Patients Receiving Ultra-high-dose Vitamin D Supplementation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to investigate the effects of achieving adequate vitamin D levels via
      ultra-high-dose vitamin D supplementation given prior to hematopoietic stem cell transplant
      on transplant-related complications and inflammatory biomarkers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 70% of patients have vitamin D deficiency prior to hematopoietic stem cell transplant
      (HSCT). Patients with sufficient Vitamin D levels (&gt;50nm/L) prior to allogeneic transplant
      have significantly better overall survival (OS) and lower rates of rejection and relapse.
      Vitamin D inhibits Th1 and augments Th2 cell development. Patients who receive vitamin D
      supplementation during allogeneic transplant have less inflammatory-mediated processes such
      as chronic graft versus host disease (GVHD) and lower levels of naïve CD8+ cells and CD40
      ligand. Multiple studies have raised concern regarding the adequacy of standard and high-dose
      vitamin D dosing for vitamin D deficiency. A single oral ultra-high dose of Vitamin D given
      prior to HSCT has been shown to be a safe and well tolerated method of sustaining therapeutic
      Vitamin D levels for 6-19 weeks.

      This is a pilot study to investigate the dynamic changes in inflammatory biomarkers following
      ultra-high-dose vitamin D supplementation. The study population is patients with total
      vitamin D level &lt;/=50ng/mL prior to HSCT.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 10, 2018</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Actual">May 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of graft-versus-host disease, veno-occlusive disease, and thrombotic microangiopathy</measure>
    <time_frame>100 days after transplant</time_frame>
    <description>Graft-versus-host disease, veno-occlusive disease, and thrombotic microangiopathy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitamin D sufficiency following Stoss dosing</measure>
    <time_frame>prior to transplant</time_frame>
    <description>Vitamin D sufficiency following Stoss dosing prior to tranpslantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of survival, relapse, and significant infections</measure>
    <time_frame>from time of transplant to 1 year after transplant</time_frame>
    <description>Clinically significant events including but not limited to survival, relapse, significant infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine levels</measure>
    <time_frame>before vitamin D is given, 1-2 weeks after vitamin D is given, day of transplant, day +7, day +14, and day +30</time_frame>
    <description>The investigators will examine changes in levels of IFN-gamma, TNF-alpha, IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10 (in pg/mL) before and after vitamin D is given</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine stimulation test</measure>
    <time_frame>before vitamin D is given, and 1-2 weeks after vitamin D is given</time_frame>
    <description>The investigators will examine changes in the immune profile (reactivity of CD45, 235, 61, 66 197, 19, 4, 38, 163, 43, 7, 62L, 127, 123, 279, 274, 14, 90, 11c, 294, 15, 16, 25, 27, 8, 33, 3, 45RA, 56, 11b; pS6, p-p38, HLA-DR, pERK 1/2, pStat3, pStat1, TCRgd, pStat5) in response to cytokine stimulation before and after vitamin D is given</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Hematopoietic Stem Cell Transplant</condition>
  <arm_group>
    <arm_group_label>Vitamin D (Cholecalciferol)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be enrolled to this arm. A single dose of ultra-high-dose vitamin D will be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>A single dose of ultra-high-dose vitamin D (cholecalciferol) will be given prior to hematopoietic stem cell transplant. Research labs including inflammatory biomarker panels will be obtained prior to and after the dose is given.</description>
    <arm_group_label>Vitamin D (Cholecalciferol)</arm_group_label>
    <other_name>vitamin D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are preparing for HSCT

          -  If a patient is receiving an autologous transplant, enrollment must occur prior to
             first transplant in the case that the patient is planned for multiple transplants

        Exclusion Criteria:

          -  Uncorrected hypocalcemia or hypophosphatemia

          -  Patients in the ICU or on renal replacement therapy

          -  Patients who have had an allogeneic transplant within the past 12 months prior to
             enrollment

        Enrolled patients with 25OHD level ≤50 ng/mL continue on study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Etan Orgel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wallace G, Jodele S, Howell J, Myers KC, Teusink A, Zhao X, Setchell K, Holtzapfel C, Lane A, Taggart C, Laskin BL, Davies SM. Vitamin D Deficiency and Survival in Children after Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2015 Sep;21(9):1627-31. doi: 10.1016/j.bbmt.2015.06.009. Epub 2015 Jun 18.</citation>
    <PMID>26093045</PMID>
  </reference>
  <reference>
    <citation>Wallace G, Jodele S, Myers KC, Dandoy CE, El-Bietar J, Nelson A, Teusink-Cross A, Khandelwal P, Taggart C, Gordon CM, Davies SM, Howell JC. Single Ultra-High-Dose Cholecalciferol to Prevent Vitamin D Deficiency in Pediatric Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 Sep;24(9):1856-1860. doi: 10.1016/j.bbmt.2018.05.019. Epub 2018 May 18.</citation>
    <PMID>29782992</PMID>
  </reference>
  <reference>
    <citation>Hansson ME, Norlin AC, Omazic B, Wikström AC, Bergman P, Winiarski J, Remberger M, Sundin M. Vitamin d levels affect outcome in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Oct;20(10):1537-43. doi: 10.1016/j.bbmt.2014.05.030. Epub 2014 Jun 5.</citation>
    <PMID>24910378</PMID>
  </reference>
  <reference>
    <citation>Caballero-Velázquez T, Montero I, Sánchez-Guijo F, Parody R, Saldaña R, Valcarcel D, López-Godino O, Ferra I Coll C, Cuesta M, Carrillo-Vico A, Sánchez-Abarca LI, López-Corral L, Márquez-Malaver FJ, Pérez-Simón JA; GETH (Grupo Español de Trasplante Hematopoyético). Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial. Clin Cancer Res. 2016 Dec 1;22(23):5673-5681. Epub 2016 Jun 29.</citation>
    <PMID>27358490</PMID>
  </reference>
  <reference>
    <citation>van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):93-101. Epub 2005 Jul 19. Review.</citation>
    <PMID>16046118</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2018</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vitamin D</keyword>
  <keyword>cytokines</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

